In Vitro Dissolution Experiment Articles & Analysis: Older
9 news found
RevBio, Inc., announced that it has been awarded the opportunity to conduct an in vivo research experiment on the International Space Station U.S. National Laboratory (ISS National Lab). This experiment will examine the biomaterial's osteoconductivity when used in a microgravity environment where bone density and the ability to regenerate new bone tissue is significantly compromised. "Given the ...
Cosmeceutical Assets Include Company’s Lead Anti-inflammatory OTC Cosmeceutical Compound called LEA™ (Limonenyldihydroxybenzyl Ethoxycarbonyl Azetidine) Company’s Strategy is to Enable Dermique to Focus on Commercializing Near Term Revenue Drivers like LEA™, Other Cosmeceuticals DOYLESTOWN, PA / ACCESSWIRE / August 24, 2021 / Neuropathix, Inc. (“Neuropathix” ...
Neuropathix, Inc. (“Neuropathix” or the “Company”) (OTCQB:NPTX), a socially responsible pain management life sciences company, announced today the publication of the global Patent Cooperation Treaty (PCT) Patent under Publication No. WO/2021/097351 “Functionalized 1,3-Benzene Diols and Their Method of Use for the Treatment of Radiation Dermatitis and Other Skin ...
Preclinical data validate that human T-cells expressing a TCR targeting mesothelin, independent of HLA recognition, can kill human tumor cells HiT works as well, or better than, a TRuC construct targeting mesothelin in preclinical studies Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, reported preclinical data from its HiT targeting mesothelin, being ...
DOYLESTOWN, Pa., April 01, 2020 (GLOBE NEWSWIRE) — Kannalife, Inc. (“Kannalife” or the “Company”) (OTCQB: KLFE), a biopharmaceutical medchem company specializing in the research and development of potent novel monotherapeutics, announced today that the Company has been issued a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for its ...
ATLANTA, October 2, 2018 – Micron Biomedical, Inc. (Micron) recently completed a feasibility study with one of its commercial partners, a top-10 pharmaceutical company. The study consisted of developing a dissolving microneedle patch with specific design attributes to meet the partner’s unique delivery requirements and to assess the microneedle patch in in-vitro and in-vivo ...
Agilent Technologies Inc. (NYSE: A) today introduced SureGuide, the first in a new series of kits to advance genome editing and synthetic biology. The complete SureGuide workflow includes a SureGuide Cas9 Nuclease Kit, SureGuide gRNA Synthesis Kit and SureGuide gRNA Control Kit, all designed to work together for any lab interested in quickly enabling next-generation genome engineering. The ...
Researchers at the Henry Ford Health System (Detroit, MI) and colleagues at Saneron CCEL Therapeutics, Inc. of Tampa, Florida, have found that when human umbilical cord blood cells (HUCBCs) were transplanted into test rats modeled with stroke, the addition of Simvastatin to the HUCBCs significantly increased the therapeutic benefit of the HUCBCs. The study was published in a recent issue of ...
Agilent Technologies, Inc. (NYSE: A) today announced it has presented the 2011 Manfred Donike Award for scientific excellence in sports-doping testing to Simon Beuck and Nicolas Leuenberger. Agilent sponsors this annual award to recognize distinguished scientific contributions in doping analysis. Award winners are scientists who exemplify the spirit and scientific leadership of doping control ...